Corey J Hayes1,2, Teresa J Hudson3,4, Martha M Phillips5, Zoran Bursac6, James S Williams4, Mark A Austin4, Mark J Edlund7,8, Bradley C Martin2,4. 1. Department of Pharmacy, Baptist Health Medical Center -Little Rock, AR, USA. 2. Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 3. Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 4. Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare System, Little Rock, AR, USA. 5. College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 6. Division of Biostatistics and Center for Population Sciences, Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. 7. Behavioral Health Epidemiology Program, RTI International, NC, USA. 8. Behavioral Health Services, St. Luke's Health System, Twin Falls, ID, USA.
Abstract
PURPOSE: Our aim is to determine if propoxyphene withdrawal from the US market was associated with opioid continuation, continued chronic opioid use, and secondary propoxyphene-related adverse events (emergency department visits, opioid-related events, and acetaminophen toxicity). METHODS: Medical service use and pharmacy data from 19/11/08 to 19/11/11 were collected from the national Veterans Healthcare Administration healthcare databases. A quasi-experimental pre-post retrospective cohort design utilizing a historical comparison group provided the study framework. Logistic regression controlling for baseline covariates was used to estimate the effect of propoxyphene withdrawal. RESULTS: There were 24,328 subjects (policy affected n = 10,747; comparison n = 13,581) meeting inclusion criteria. In the policy-affected cohort, 10.6% of users ceased using opioids, and 26.6% stopped chronic opioid use compared with 3.8% and 13.5% in the historical comparison cohort, respectively. Those in the policy-affected cohort were 2.7 (95%CI: 2.5-2.8) and 3.2 (95%CI: 2.9-3.6) times more likely than those in the historical comparison cohort to discontinue chronic opioid and any opioid use, respectively. Changes in adverse events and Emergency Department (ED) visits were not different between policy-affected and historical comparison cohorts (p > 0.05). CONCLUSIONS: The withdrawal of propoxyphene-containing products resulted in rapid and virtually complete elimination in propoxyphene prescribing in the veterans population; however, nearly 90% of regular users of propoxyphene switched to an alternate opioid, and three quarters continued to use opioids chronically.
PURPOSE: Our aim is to determine if propoxyphene withdrawal from the US market was associated with opioid continuation, continued chronic opioid use, and secondary propoxyphene-related adverse events (emergency department visits, opioid-related events, and acetaminophentoxicity). METHODS: Medical service use and pharmacy data from 19/11/08 to 19/11/11 were collected from the national Veterans Healthcare Administration healthcare databases. A quasi-experimental pre-post retrospective cohort design utilizing a historical comparison group provided the study framework. Logistic regression controlling for baseline covariates was used to estimate the effect of propoxyphene withdrawal. RESULTS: There were 24,328 subjects (policy affected n = 10,747; comparison n = 13,581) meeting inclusion criteria. In the policy-affected cohort, 10.6% of users ceased using opioids, and 26.6% stopped chronic opioid use compared with 3.8% and 13.5% in the historical comparison cohort, respectively. Those in the policy-affected cohort were 2.7 (95%CI: 2.5-2.8) and 3.2 (95%CI: 2.9-3.6) times more likely than those in the historical comparison cohort to discontinue chronic opioid and any opioid use, respectively. Changes in adverse events and Emergency Department (ED) visits were not different between policy-affected and historical comparison cohorts (p > 0.05). CONCLUSIONS: The withdrawal of propoxyphene-containing products resulted in rapid and virtually complete elimination in propoxyphene prescribing in the veterans population; however, nearly 90% of regular users of propoxyphene switched to an alternate opioid, and three quarters continued to use opioids chronically.
Authors: Bradley C Martin; Ming-Yu Fan; Mark J Edlund; Andrea Devries; Jennifer Brennan Braden; Mark D Sullivan Journal: J Gen Intern Med Date: 2011-07-13 Impact factor: 5.128
Authors: Mark J Edlund; Bradley C Martin; Andrea Devries; Ming-Yu Fan; Jennifer Brennan Braden; Mark D Sullivan Journal: Clin J Pain Date: 2010-01 Impact factor: 3.442
Authors: Daniel J Cobaugh; Carl Gainor; Cynthia L Gaston; Tai C Kwong; Barbarajean Magnani; Mary Lynn McPherson; Jacob T Painter; Edward P Krenzelok Journal: Am J Health Syst Pharm Date: 2014-09-15 Impact factor: 2.637
Authors: Molly M Jeffery; Nancy E Morden; Marc Larochelle; Nilay D Shah; W Michael Hooten; Ellen Meara Journal: Med Care Date: 2020-01 Impact factor: 3.178
Authors: Andrea C Enzinger; Kaushik Ghosh; Nancy L Keating; David M Cutler; Mary Beth Landrum; Alexi A Wright Journal: J Clin Oncol Date: 2021-07-22 Impact factor: 50.717